title: Prospective, randomized study comparing highly purified urinary follicle-stimulating hormone (FSH) and recombinant FSH for in vitro fertilization/intracytoplasmic sperm injection in patients with polycystic ovary syndrome.
abstract: In a randomized study comparing purified urinary FSH with recombinant FSH for IVF/intracytoplasmic sperm injection in patients with polycystic ovary syndrome, there was no significant difference between the mean total dose of FSH used, duration of stimulation, number of retrieved oocytes, number of mature oocytes, number of embryos transferred, or the ongoing pregnancy rate between the two groups. However, there were significantly more fertilized oocytes, a higher fertilization rate, more top-quality embryos, and more cryopreserved embryos in the urinary FSH group.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt. ghar@link.net
authors.forename: Mohamed
authors.initials: M
authors.lastname: Aboulghar
authors.forename: Waleed
authors.initials: W
authors.lastname: Saber
authors.forename: Yahia
authors.initials: Y
authors.lastname: Amin
authors.forename: Mona
authors.initials: M
authors.lastname: Aboulghar
authors.forename: Ragaa
authors.initials: R
authors.lastname: Mansour
authors.forename: Gamal
authors.initials: G
authors.lastname: Serour
mesh_terms: D000328:Adult; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D005640:Follicle Stimulating Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy* / Q000209:etiology; D016471:Ovarian Hyperstimulation Syndrome / Q000517:prevention & control; D010062:Ovulation Induction / Q000379:methods; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy*; D011247:Pregnancy; D018873:Pregnancy Rate; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D020554:Sperm Injections, Intracytoplasmic / Q000379:methods; D016896:Treatment Outcome; D050477:Urofollitropin / Q000009:adverse effects / Q000302:isolation & purification / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D011994:Recombinant Proteins; D050477:Urofollitropin; D005640:Follicle Stimulating Hormone